Kaiyue Yang's questions to Schrodinger Inc (SDGR) leadership • Q4 2024
Question
Kaiyue Yang, on behalf of Michael Yee, inquired about the assumptions behind the 2025 drug discovery revenue guidance, specifically the contribution from the Novartis partnership, and asked for updated thoughts on the competitive landscape for the MALT1 program.
Answer
CFO Geoffrey Porges explained that the forecasted increase in drug discovery revenue is broad-based, stemming from the Novartis collaboration amortization as well as expanded programs with Lilly and Otsuka. President of R&D, Therapeutics, Karen Akinsanya, stated that for the MALT1 program, the primary focus is on defining the profile of their own molecule, SGR-1505, with initial data expected in Q2.